AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...
AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback